Metz Tumor Progress Express (Issue 018)

Editor's note: Metz Medical will regularly summarize the latest developments in the oncology field
.

The following is the latest tumor progression presented to you

Editor's note: Metz Medical will regularly summarize the latest developments in the oncology field

Metz Cancer Progress Express (Issue 017) Metz Cancer Progress Express (Issue 017) Metz Cancer Progress Express (Issue 017)

1.
Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer!

1.
Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer! 1.
Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer! 1.
Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer!

Recently, published in a journal Radiology Research at a switching unipolar mode, evaluated using a separable clusters electrode non-contact clinical RFA treatment of small HCC (2.
5 cm) of the prognosis , clinical improve small HCC treatment prognosis Provides valuable imaging methods and provides strong support for the wide application of contactless RFA .

Recently, published in a journal Radiology Research at a switching unipolar mode, evaluated using a separable clusters electrode non-contact clinical RFA treatment of small HCC (2.

5 cm) of the prognosis , clinical improve small HCC treatment prognosis Provides valuable imaging methods and provides strong support for the wide application of contactless RFA .

Study in November 2017 to January 2019 period for all the programs using the contactless RFA, is less 2.

5 cm single HCC patients included in the assessment

Study in November 2017 to January 2019 period for all the programs using the contactless RFA, is less 2.
5 cm single HCC patients included in the assessment

This study shows that for patients with small hepatocellular carcinoma (HCC) 2.

For details refer to: Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer! For more information: For more information:Radiology: Have you heard of contactless radiofrequency ablation? Another choice for patients with small liver cancer!

2.
Radioology: For ductal carcinoma in situ, breast MRI not only prompts the diagnosis , but also predicts the prognosis!

2.
Radioology: For ductal carcinoma in situ, breast MRI not only prompts the diagnosis , but also predicts the prognosis! 2.
Radioology: For ductal carcinoma in situ, breast MRI not only prompts the diagnosis , but also predicts the prognosis! diagnosis

Studies have shown that enhanced MRI has the highest sensitivity for the detection of DCIS, and the description of its scope has the greatest accuracy
.

However, a number of published research reports have shown that the relationship between MRI features and DCIS features is different, and the results have selection bias

In order to meet the needs of optimizing the treatment of DCIS and clarify the impact of MRI on the results, the Eastern Cooperative Oncology Group-American Society of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group conducted a phase E4112 single-arm multicenter trial
.

All selected women were selected for extensive local resection (WLE) based on the results of routine imaging (mammography, with or without US) before MRI

Recently, the research team published a secondary analysis of the study in the journal Radiology, which explored the relationship between baseline clinical covariates, qualitative MRI features, and DCIS scores, and evaluated the diagnostic accuracy of MRI, which is accurate for DCIS patients.
The diagnosis and the formulation of the best treatment plan provide valuable data support
.

This study is a secondary analysis of a multi-center prospective clinical trial of the ECOG-ACRIN Cancer Research Group.
The patients included in this study were DCIS diagnosed with conventional imaging techniques (mammography and the United States) and passed the core The diagnosis was confirmed by needle biopsy (CNB) and was enrolled between March 2015 and April 2016.
According to the results of routine imaging and clinical examination, patients with extensive local resection (WLE)
.

For details, please refer to: Radiology: For ductal carcinoma in situ, breast MRI not only prompts the diagnosis, but also predicts the prognosis!

For more information: For more information: For more information:Radiology: For ductal carcinoma in situ, breast MRI not only prompts the diagnosis, but also predicts the prognosis!

3.
Gastroenterology: In a study of nearly 30,000 Chinese people, these behaviors caused half of the occurrence of gastric cancer!

3.
Gastroenterology: In a study of nearly 30,000 Chinese people, these behaviors caused half of the occurrence of gastric cancer! 3.
Gastroenterology: In a study of nearly 30,000 Chinese people, these behaviors caused half of the occurrence of gastric cancer!

By studying the time trends of related life>
.

To this end, researchers from Harvard University’s TH Chan School of Public Health analyzed data from the China Health and Nutrition Survey (CHNS), and the results were published in the recent Gastroenterology journal

By studying the time trends of related life>

Researchers estimated the time trends of life>

The results showed that in 2011, 56.
5% of colon cancer , 59.
8% of gastric cancer, 48.
5% of esophageal cancer and 35.
2% of liver cancer in China were caused by the life>
.
The latter include smoking, eating too much red meat, obesity, alcohol consumption, high sodium diet, inadequate consumption of fruits, high processed meat, dairy, pickled vegetable intake, lack of physical activity, low dietary fiber and vegetable diet
.
The results showed that in 2011, 56.
5% of colon cancer , 59.
8% of gastric cancer, 48.
5% of esophageal cancer and 35.
2% of liver cancer in China were caused by the life>
.
The latter include smoking, eating too much red meat, obesity, alcohol consumption, high sodium diet, inadequate consumption of fruits, high processed meat, dairy, pickled vegetable intake, lack of physical activity, low dietary fiber and vegetable diet
.
In 2011, 56.
5% of colon cancer , 59.
8% of gastric cancer, 48.
5% of esophageal cancer, and 35.
2% of liver cancer in China were caused by the life>
.
The latter include smoking, eating too much red meat, obesity, alcohol consumption, high sodium diet, inadequate consumption of fruits, high processed meat, dairy, pickled vegetable intake, lack of physical activity, low dietary fiber and vegetable diet
.
In 2011, 56.
5% of colon cancer , 59.
8% of gastric cancer, 48.
5% of esophageal cancer, and 35.
2% of liver cancer in China were caused by the life>
.
The latter include smoking, eating too much red meat, obesity, alcohol consumption, high sodium diet, inadequate consumption of fruits, high processed meat, dairy, pickled vegetable intake, lack of physical activity, low dietary fiber and vegetable diet
.
Colon cancer

Studies have shown that if people can change their unhealthy life>prevented
.

Studies have shown that if people can change their unhealthy life>prevented
.
Studies have shown that if people can change their unhealthy life>prevented
.
If people can change their unhealthy life>prevented
.
prevention

For details, refer to: Gastroenterology: A study of nearly 30,000 Chinese people.
These behaviors cause half of the occurrence of gastric cancer!

For details, refer to: Gastroenterology: A study of nearly 30,000 Chinese people.
These behaviors cause half of the occurrence of gastric cancer! For details, refer to: Gastroenterology: A study of nearly 30,000 Chinese people.
These behaviors cause half of the occurrence of gastric cancer! For details, refer to:Gastroenterology: A study of nearly 30,000 Chinese people.
These behaviors cause half of the occurrence of gastric cancer! For more information: Formore information:Gastroenterology: In a study of nearly 30,000 Chinese, these behaviors caused half of the occurrence of gastric cancer!

4.
Cancer: The fear of tumor recurrence and disease progression in long-term survivors after radical prostatectomy: a longitudinal study

4.
Cancer: Fear of tumor recurrence and disease progression of long-term survivors after radical prostatectomy : a longitudinal study 4.
Cancer: Fear of tumor recurrence and disease progression of long-term survivors after radical prostatectomy: a longitudinal study

Although the fear of cancer recurrence (FCR) or disease progression is one of the most recognized unmet needs and concerns of cancer survivors, research on FCR among long-term survivors is lacking
.
Recently, researchers have longitudinally evaluated the incidence and predictive factors of FCR in long-term prostate cancer (PCa) survivors
.

Although the fear of cancer recurrence (FCR) or disease progression is one of the most recognized unmet needs and concerns of cancer survivors, research on FCR among long-term survivors is lacking
.
Recently, researchers have longitudinally evaluated the incidence and predictive factors of FCR in long-term prostate cancer (PCa) survivors
.
Although the fear of cancer recurrence (FCR) or disease progression is one of the most recognized unmet needs and concerns of cancer survivors, research on FCR among long-term survivors is lacking
.
Recently, researchers have longitudinally evaluated the incidence and predictive factors of FCR in long-term prostate cancer (PCa) survivors
.

The study cohort included 2,417 survivors from the German multicenter familial prostate cancer database.
They completed their fears after an average of 7 years after radical prostatectomy (T1 in 2010) and 9 years later (T2 in 2019).
Progress questionnaire-short form
.
The stratified multivariate logistic regression method was used to evaluate the predictors of FCR at follow-up
.

The study cohort included 2,417 survivors from the German multicenter familial prostate cancer database.
They completed their fears after an average of 7 years after radical prostatectomy (T1 in 2010) and 9 years later (T2 in 2019).
Progress questionnaire-short form
.
The stratified multivariate logistic regression method was used to evaluate the predictors of FCR at follow-up
.
The study cohort included 2,417 survivors from the German multicenter familial prostate cancer database.
They completed their fears after an average of 7 years after radical prostatectomy (T1 in 2010) and 9 years later (T2 in 2019).
Progress questionnaire-short form
.
The stratified multivariate logistic regression method was used to evaluate the predictors of FCR at follow-up
.

Studies have shown that FCR is still a burden for some PCa survivors, even after they have been diagnosed and treated for many years
.
Medical care professionals should detect FCR and identify patients at risk, so as to provide appropriate psychosocial care to avoid FCR causing damage to the quality of life and mental health
.

Studies have shown that FCR is still a burden for some PCa survivors, even after they have been diagnosed and treated for many years
.
Medical care professionals should detect FCR and identify patients at risk, so as to provide appropriate psychosocial care to avoid FCR causing damage to the quality of life and mental health
.
Studies have shown that FCR is still a burden for some PCa survivors, even after they have been diagnosed and treated for many years
.
Medical care professionals should detect FCR and identify patients at risk, so as to provide appropriate psychosocial care to avoid FCR causing damage to the quality of life and mental health
.
FCR is still a burden for some PCa survivors, even after they have been diagnosed and treated for many years.
FCR is still a burden for some PCa survivors, even after they have been diagnosed and treated for many years.

For more details: Cancer: Long-term survivors' fear of tumor recurrence and disease progression after radical prostatectomy: a longitudinal study

For more information: Cancer: Fear of tumor recurrence and disease progression in long-term survivors after radical prostatectomy: A longitudinal study For details: Cancer:Fear oflong-term survivors after radical prostatectomy on tumor recurrence and disease progression: One Longitudinal studydetails:Reference fordetails:Reference fordetails:Cancer: Fear of tumor recurrence and disease progression in long-term survivors after radical prostatectomy: A longitudinal study

5.
J Clin Oncol: Do you need radiotherapy after resection of high-risk ductal carcinoma in situ?

5.
J Clin Oncol: Do you need radiotherapy after resection of high-risk ductal carcinoma in situ? 5.
J Clin Oncol: Do you need radiotherapy after resection of high-risk ductal carcinoma in situ?

It is understood that NRG/RTOG 9804 is the only randomized trial evaluating the effect of whole breast radiation (radiotherapy [RT]) and observation (OBS) on the prognosis of patients with high-risk ductal carcinoma in situ (DCIS) after breast tumor resection
.

It is understood that NRG/RTOG 9804 is the only randomized trial evaluating the effect of whole breast radiation (radiotherapy [RT]) and observation (OBS) on the prognosis of patients with high-risk ductal carcinoma in situ (DCIS) after breast tumor resection
.

The test patient was a DCIS patient who underwent breast tumor resection.
X-ray examination was required to show that the tumor size was no more than 2.
5 cm, the final margin was ≥ 3 mm, and the nuclear grade was low or medium
.
The use of tamoxifen is not restricted
.
Eligible patients were randomly assigned to the RT group or OBS group
.
The primary endpoint is ipsilateral breast recurrence (IBR)
.

The test patient was a DCIS patient who underwent breast tumor resection.
X-ray examination was required to show that the tumor size was no more than 2.
5 cm, the final margin was ≥ 3 mm, and the nuclear grade was low or medium
.
The use of tamoxifen is not restricted
.
Eligible patients were randomly assigned to the RT group or OBS group
.
The primary endpoint is ipsilateral breast recurrence (IBR)
.
The test patient was a DCIS patient who underwent breast tumor resection.
X-ray examination was required to show that the tumor size was no more than 2.
5 cm, the final margin was ≥ 3 mm, and the nuclear grade was low or medium
.
The use of tamoxifen is not restricted
.
Eligible patients were randomly assigned to the RT group or OBS group
.
The primary endpoint is ipsilateral breast recurrence (IBR)
.

Studies have shown that radiotherapy can significantly reduce all and aggressive IBR in patients with high-risk DCIS, and the benefits can last for 15 years
.
However, the results of this study are not an absolute indication for such patients to undergo radiotherapy.
Instead, patients should be fully informed of the effect of whole breast radiotherapy on reducing the risk of long-term ipsilateral breast recurrence after breast tumor resection.
The patient and the doctor jointly decide whether or not to receive radiotherapy
.

Studies have shown that radiotherapy can significantly reduce all and aggressive IBR in patients with high-risk DCIS, and the benefits can last for 15 years
.
However, the results of this study are not an absolute indication for such patients to undergo radiotherapy.
Instead, patients should be fully informed of the effect of whole breast radiotherapy on reducing the risk of long-term ipsilateral breast recurrence after breast tumor resection.
The patient and the doctor jointly decide whether or not to receive radiotherapy
.
Studies have shown that radiotherapy can significantly reduce all and aggressive IBR in patients with high-risk DCIS, and the benefits can last for 15 years
.
However, the results of this study are not an absolute indication for such patients to undergo radiotherapy.
Instead, patients should be fully informed of the effect of whole breast radiotherapy on reducing the risk of long-term ipsilateral breast recurrence after breast tumor resection.
The patient and the doctor jointly decide whether or not to receive radiotherapy
.
Radiotherapy can significantly reduce all and aggressive IBR in patients with high-risk DCIS, and the benefit can last for 15 years.
Radiotherapy can significantly reduce all and aggressive IBR in patients with high-risk DCIS, and the benefit can last for 15 years

For details, please refer to: J Clin Oncol: Is radiotherapy required after resection of high-risk ductal carcinoma in situ of breast?

For details, please refer to: J Clin Oncol: Is radiotherapy required after resection of high-risk ductal carcinoma in situ of breast? For details, please refer to: J Clin Oncol: Is radiotherapy required after resection of high-risk ductal carcinoma in situ of breast? For details refer to: Fordetails refer to: Fordetails refer to:J Clin Oncol: Is radiotherapy required after resection of high-risk breast ductal carcinoma in situ?

6.
Cancer Cell: Sequential combination therapy can make the treatment more effective for patients with aggressive cancer!

6.
Cancer Cell: Sequential combination therapy can make the treatment more effective for patients with aggressive cancer! 6.
Cancer Cell: Sequential combination therapy can make the treatment more effective for patients with aggressive cancer!

Recent studies have shown that combining immune checkpoint inhibitors targeting PD-1/L1 with MAPK targeted therapies (usually used alone to treat cancer patients) may help overcome treatment resistance
.
However, in their new job, a UCLA team found that simply starting treatment at the same time was not the best option
.
On the contrary, starting treatment with two doses of anti-PD-1/L1 and then adding MAPK targeted therapy is more effective in prolonging tumor shrinkage and preventing the development of drug resistance
.

In this study published on Cancer Cell, researchers tested different sequential combinations in a variety of animal models of human melanoma, pancreatic cancer, and colorectal cancer.
These models consist of BRAF, NF1, NRAS, and KRAS.
Common mutation drivers of genes
.

The team also proved that prior to the addition of MAPK inhibitors, a reasonable order of anti-PD-1/L1 treatment can inhibit melanoma brain metastasis and improve the survival rate of mice
.

Researchers have detected powerful clonal expansion of T cells in all body parts to which the cancer has spread, including the brain
.
The research team found that the introduction of two immune checkpoint therapies: anti-PD-1/L1 and anti-CTLA-4, further eliminated the spread of cancer, including spread to the brain and prolonged the survival of mice
.

For details, please refer to: Cancer Cell: Sequential combination therapy can make the treatment more effective for patients with aggressive cancer!

For more information: For more information: For more information: Formore information: Formore information:Cancer Cell: Sequential combination therapy can make the treatment more effective for patients with aggressive cancer!

7.
Liver Cancer: The use of antibiotics during treatment with Immune Checkpoint Inhibitor (ICI) in patients with hepatocellular carcinoma shortens survival time

7.
Liver Cancer: The use of antibiotics during the treatment of hepatocellular carcinoma patients with immune checkpoint inhibitors (ICI) shortens the survival time 7.
Liver Cancer: The use of antibiotics during the treatment of hepatocellular carcinoma patients with immune checkpoint inhibitors (ICI) shortens the survival time

Recent studies have shown that the use of antibiotics may interfere with the efficacy of immune checkpoint inhibitors (ICI)
.
Currently in hepatocellular carcinoma (HCC), the application of immune checkpoint inhibitors (ICI) is becoming more and more widespread
.
However, it is not clear whether the use of antibiotics when applying ICI therapy in HCC affects the prognosis of patients
.
Therefore, a research team from the Shenzhen Hospital of the University of Hong Kong in China conducted a retrospective study to evaluate the relationship between the use of antibiotics during ICI treatment and the prognosis of patients with advanced hepatocellular carcinoma
.
Related results were published in Liver Cancer magazine
.

Recent studies have shown that the use of antibiotics may interfere with the efficacy of immune checkpoint inhibitors (ICI)
.
Currently in hepatocellular carcinoma (HCC), the application of immune checkpoint inhibitors (ICI) is becoming more and more widespread
.
However, it is not clear whether the use of antibiotics when applying ICI therapy in HCC affects the prognosis of patients
.
Therefore, a research team from the Shenzhen Hospital of the University of Hong Kong in China conducted a retrospective study to evaluate the relationship between the use of antibiotics during ICI treatment and the prognosis of patients with advanced hepatocellular carcinoma
.
Related results were published in Liver Cancer magazine
.
Recent studies have shown that the use of antibiotics may interfere with the efficacy of immune checkpoint inhibitors (ICI)
.
Currently in hepatocellular carcinoma (HCC), the application of immune checkpoint inhibitors (ICI) is becoming more and more widespread
.
However, it is not clear whether the use of antibiotics when applying ICI therapy in HCC affects the prognosis of patients
.
Therefore, a research team from the Shenzhen Hospital of the University of Hong Kong in China conducted a retrospective study to evaluate the relationship between the use of antibiotics during ICI treatment and the prognosis of patients with advanced hepatocellular carcinoma
.
Related results were published in Liver Cancer magazine
.

The study is a regional retrospective cohort study, including all patients with advanced HCC who received ICIs (nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019
.
Exclusion criteria included previous liver transplantation and the use of cabo-zantinib, regorafenib, or ramucirumab
.
The use of antibiotics is defined as the simultaneous use of antibiotics within 30 days before or after the start of ICI
.
Use the propensity score (PS) 1:2 to match the covariates and divide them into the exposed group and the non-exposed group, and calculate the adjusted risk ratio (aHR) of cancer-related mortality and all-cause mortality related to antibiotic use.
The covariates include baseline characteristics , Causes of liver cirrhosis, Child-Pugh status, previous HCC treatments, comorbidities, and laboratory results of concurrent medications including alpha-fetoprotein
.

The study is a regional retrospective cohort study, including all patients with advanced HCC who received ICIs (nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019
.
Exclusion criteria included previous liver transplantation and the use of cabo-zantinib, regorafenib, or ramucirumab
.
The use of antibiotics is defined as the simultaneous use of antibiotics within 30 days before or after the start of ICI
.
Use the propensity score (PS) 1:2 to match the covariates and divide them into the exposed group and the non-exposed group, and calculate the adjusted risk ratio (aHR) of cancer-related mortality and all-cause mortality related to antibiotic use.
The covariates include baseline characteristics , Causes of liver cirrhosis, Child-Pugh status, previous HCC treatment, comorbidities, and laboratory results of concurrent medications including alpha-fetoprotein
.
The study is a regional retrospective cohort study, including all patients with advanced HCC who received ICIs (nivolumab, pembrolizumab, or ipilimumab) between January 2014 and December 2019
.
Exclusion criteria included previous liver transplantation and the use of cabo-zantinib, regorafenib, or ramucirumab
.
The use of antibiotics is defined as the simultaneous use of antibiotics within 30 days before or after the start of ICI
.
Use the propensity score (PS) 1:2 to match the covariates and divide them into the exposed group and the non-exposed group, and calculate the adjusted risk ratio (aHR) of cancer-related mortality and all-cause mortality related to antibiotic use.
The covariates include baseline characteristics , Causes of liver cirrhosis, Child-Pugh status, previous HCC treatment, comorbidities, and laboratory results of concurrent medications including alpha-fetoprotein
.
The use of antibiotics is defined as the simultaneous use of antibiotics within 30 days before or after the start of ICI
.

Studies have shown that the use of antibiotics during treatment with immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma (HCC) shortens survival time
.

Studies have shown that the use of antibiotics during treatment with immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma (HCC) shortens survival time
.
Studies have shown that the use of antibiotics during immune checkpoint inhibitor (ICI) treatment in patients with hepatocellular carcinoma (HCC) shortens survival time
.
Studies have shown that the use of antibiotics during treatment with immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma (HCC) shortens survival time
.
Studies have shown that the use of antibiotics during treatment with immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma (HCC) shortens survival time
.

For details, please refer to: Liver Cancer: The use of antibiotics during treatment with Immune Checkpoint Inhibitors (ICI) in patients with hepatocellular carcinoma shortens survival time

Details Reference: Liver Cancer: During the use of antibiotics shortened survival time (ICI) treating hepatocellular carcinoma patients immunized check point depressants details Reference: Liver Cancer: During the use of antibiotics shortened survival time (ICI) treating hepatocellular carcinoma patients immunized check point depressantFor more information: Formore information: Formore information: Formore information: Formore information:Liver Cancer: Immune checkpoint inhibitors (ICI) in patients with hepatocellular carcinoma use antibiotics to shorten survival time during treatmentLiver Cancer: Immune checkpoint inhibitors for patients with hepatocellular carcinoma ( ICI) The use of antibiotics during treatment shortens survival time

8.
NEJM: Analysis of the efficacy of adjuvant pembrolizumab after nephrectomy in patients with renal cell carcinoma

8.
NEJM: Analysis of the efficacy of adjuvant pembrolizumab after nephrectomy in patients with renal cell carcinoma 8.
NEJM: Analysis of the efficacy of adjuvant pembrolizumab after nephrectomy in patients with renal cell carcinoma

Recently, the top medical journal NEJM published a research article.
In this double-blind phase 3 trial, researchers randomly assigned patients with clear cell renal cancer with a high risk of recurrence after nephrectomy at a ratio of 1:1.
Do not accept metastasis resection (dose of 200 mg) or placebo intravenously every 3 weeks for a maximum of 17 cycles (about 1 year)
.
According to the investigator's assessment, the primary endpoint of the study is disease-free survival
.
Overall survival is a key secondary endpoint
.
Safety is also an important secondary end point
.

Recently, the top medical journal NEJM published a research article.
In this double-blind phase 3 trial, researchers randomly assigned patients with clear cell renal cancer with a high risk of recurrence after nephrectomy at a ratio of 1:1.
Do not accept metastasis resection (dose of 200 mg) or placebo intravenously every 3 weeks for a maximum of 17 cycles (about 1 year)
.
According to the investigator's assessment, the primary endpoint of the study is disease-free survival
.
Overall survival is a key secondary endpoint
.
Safety is also an important secondary end point
.
Recently, the top medical journal NEJM published a research article.
In this double-blind phase 3 trial, researchers randomly assigned patients with clear cell renal cancer with a high risk of recurrence after nephrectomy at a ratio of 1:1.
Do not accept metastasis resection (dose of 200 mg) or placebo intravenously every 3 weeks for a maximum of 17 cycles (about 1 year)
.
According to the investigator's assessment, the primary endpoint of the study is disease-free survival
.
Overall survival is a key secondary endpoint
.
Safety is also an important secondary end point
.

The study included 496 patients who were randomly assigned to receive pembrolizumab and 498 patients who received placebo
.
In the pre-set interim analysis, the median time from randomization to the data cutoff date was 24.
1 months
.
Pembrolizumab treatment is associated with longer disease-free survival compared with placebo (disease-free survival of 24 months, 77.
3% and 68.
1%; risk ratio of recurrence or death is 0.
68; 95% confidence interval [ CI] is 0.
53 to 0.
87; P=0.
002)
.

The study included 496 patients who were randomly assigned to receive pembrolizumab and 498 patients who received placebo
.
In the pre-set interim analysis, the median time from randomization to the data cutoff date was 24.
1 months
.
Pembrolizumab treatment is associated with longer disease-free survival compared with placebo (disease-free survival of 24 months, 77.
3% and 68.
1%; risk ratio of recurrence or death is 0.
68; 95% confidence interval [ CI] is 0.
53 to 0.
87; P=0.
002)
.
The study included 496 patients who were randomly assigned to receive pembrolizumab and 498 patients who received placebo
.
In the pre-set interim analysis, the median time from randomization to the data cutoff date was 24.
1 months
.
Pembrolizumab treatment is associated with longer disease-free survival compared with placebo (disease-free survival of 24 months, 77.
3% and 68.
1%; risk ratio of recurrence or death is 0.
68; 95% confidence interval [ CI] is 0.
53 to 0.
87; P=0.
002)
.

Studies have shown that in kidney cancer patients with a high risk of recurrence, pembrolizumab treatment significantly improved disease-free survival after surgery compared with placebo
.

Studies have shown that in patients with kidney cancer at high risk of recurrence, pembrolizumab treatment significantly improved disease-free survival after surgery compared with placebo
.
Studies have shown that in patients with kidney cancer at high risk of recurrence, pembrolizumab treatment significantly improved disease-free survival after surgery compared with placebo
.
In kidney cancer patients with a high risk of recurrence, pembrolizumab treatment significantly improved disease-free survival after surgery compared with placebo
.

For details, please refer to: NEJM: Analysis of the efficacy of adjuvant pembrolizumab after nephrectomy in patients with renal cell carcinoma

Reference for details: Reference fordetails:Reference fordetails:Reference for details: Reference for details:Reference fordetails:Reference fordetails:NEJM: Analysis of the efficacy of adjuvant pembrolizumab after nephrectomy in patients with renal cancer

9.
JAMA Sub-Journal: Data of over 10 million people, "Daily Drinking" or "Weekend Booze", which one is more carcinogenic?

9.
JAMA Sub-Journal: Data of over 10 million people, "Daily Drinking" or "Weekend Booze", which one is more carcinogenic? 9.
JAMA Sub-Journal: Data of over 10 million people, "Daily Drinking" or "Weekend Booze", which one is more carcinogenic?

A study reported that increased frequency of alcohol consumption was associated with increased risk of cancers of the colon, mouth, pharynx, larynx, liver, and esophagus in men, but the opposite was true in women
.
The study is also limited by the small incidence of results, which limits the statistical power of individual cancers
.
Therefore, it is not clear which one is more important, the frequency of drinking or the number of drinks per drink
.

To assess the frequency of alcohol consumption and alcohol consumption each and digestive relative relationship tract cancer development, epidemiology experts from Seoul National University to carry out the research, published in the JAMA  journal Open Network
.

Digest JAMA

This is a population-based retrospective cohort study using data from the Korean National Health Insurance System database.
These data are from 11,737,467 cancer-free participants who underwent the National Health Checkup Program from January 1, 2009 to December 31, 2010 The person
.
Participants from the health screening start date of the second year of follow-up, until they digestive tract cancer diagnosis , death, or December 31, 2017
.

Screening Digestive Diagnosis

In this cohort study, frequent alcohol consumption is a more important risk factor for gastrointestinal cancer, rather than the amount of alcohol consumed each time
.
In addition to the total amount of alcohol consumed or the amount of alcohol consumed per drink, individuals should be reminded to drink small amounts of alcohol on a regular basis
.

In this cohort study, frequent alcohol consumption is a more important risk factor for gastrointestinal cancer, rather than the amount of alcohol consumed each time
.
In addition to the total amount of alcohol consumed or the amount of alcohol consumed per drink, individuals should be reminded to drink small amounts of alcohol on a regular basis
.
In this cohort study, frequent alcohol consumption is a more important risk factor for gastrointestinal cancer, rather than the amount of alcohol consumed each time
.
In addition to the total amount of alcohol consumed or the amount of alcohol consumed per drink, individuals should be reminded to drink small amounts of alcohol on a regular basis
.

For details, please refer to: JAMA Sub-Journal: Data of over 10 million people, "Daily Drinking" or "Weekend Booze", which one is more carcinogenic?

Reference for details: Reference fordetails:Reference fordetails:Reference for details: Reference for details:Reference fordetails:Reference fordetails:JAMA Sub-Journal: Data of over 10 million people, "Daily drinking" or "Weekend booze", which one is more carcinogenic?

10.
PLOS Med: Cancer may also be "sad"? Let's take a look at the heart risk stratification of cancer patients

10.
PLOS Med: Cancer may also be "sad"? Let's take a look at the heart risk stratification of cancer patients.
10.
PLOS Med: Cancer may also be "sad"? Let's take a look at the heart risk stratification of cancer patients

The increasing awareness of CTRCD has led to the emergence of the emerging field of cardiac oncology
.
However, due to the lack of predictive and prognostic testing methods, there are limited guidelines on how to assess, prevent, and treat CTRCD in cancer survivors
.
Echocardiography is the most commonly used clinical test to evaluate CTRCD
.
The American Society of Echocardiography (ASE) defines cardiac insufficiency as a left ventricular ejection fraction (LVEF) below 10% of the lower limit of normal
.

Prevention The American Society for Echocardiography (ASE) defines cardiac insufficiency as a left ventricular ejection fraction (LVEF) below 10% of the lower limit of normal
.
The American Society of Echocardiography (ASE) defines cardiac insufficiency as a left ventricular ejection fraction (LVEF) below 10% of the lower limit of normal
.

However, the traditional echocardiographic method alone has its limitations, including a high false positive rate
.
In addition, when the LVEF was found to be reduced, the intervention was too late, because only 42% of patients were able to partially or completely restore left ventricular function
.
Next-generation machine learning technology can use the power of large-scale clinical data to provide new possibilities for predicting which patients are at risk and allowing early intervention to prevent cardiovascular disease risks
.

When the LVEF was found to be reduced, the intervention was already very late, because only 42% of patients were able to partially or completely restore left ventricular function
.
When the LVEF was found to be reduced, the intervention was already very late, because only 42% of patients were able to partially or completely restore left ventricular function
.

It can be seen that people's understanding of how to predict which patients will have adverse cardiac outcomes is still very limited
.
To this end, experts from the Institute of Genomic Medicine at the Lerner Institute of the Cleveland Clinic in the United States have carried out relevant research, aiming to use large-scale institutional electronic medical records to unbiased cardiac risk stratification for cancer patients
.
The results were published in the recent PLOS Med magazine
.

The study proved that the patient-patient network clustering method is clinically intuitive, and it can more quickly identify cancer survivors who are at greater risk of cardiac dysfunction
.
We believe that this research has great hope for identifying new cardiac risk subgroups and clinically operable variables to promote the development of accurate cardio-cerebrovascular disease
.

The study proved that the patient-patient network clustering method is clinically intuitive, and it can more quickly identify cancer survivors who are at greater risk of cardiac dysfunction
.
We believe that this research has great hope for identifying new cardiac risk subgroups and clinically operable variables to promote the development of accurate cardio-cerebrovascular disease
.
The study proved that the patient-patient network clustering method is clinically intuitive, and it can more quickly identify cancer survivors who are at greater risk of cardiac dysfunction
.
We believe that this research has great hope for identifying new cardiac risk subgroups and clinically operable variables to promote the development of accurate cardio-cerebrovascular disease
.
Precise

For details, please refer to: PLOS Med: Cancer may also be "sad"? Let's take a look at the heart risk stratification of cancer patients

For more information: For more information: For more information: Formore information: Formore information: Formore information: Formore information:PLOS Med: Cancer may also be "sad"? Let's take a look at the heart risk stratification of cancer patients

 

Leave a message here